Introduction to "Effects of per- and polyfluoroalkyl substances (PFAS) within a developmental context".

Neurotoxicol Teratol

Department of Psychological and Brain Sciences, University of Massachusetts, Amherst, MA 01003, United States of America.

Published: August 2024


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ntt.2024.107372DOI Listing

Publication Analysis

Top Keywords

introduction "effects
4
"effects per-
4
per- polyfluoroalkyl
4
polyfluoroalkyl substances
4
substances pfas
4
pfas developmental
4
developmental context"
4
introduction
1
per-
1
polyfluoroalkyl
1

Similar Publications

IntroductionThe use of digital solutions including patient-reported outcomes is limited to follow-up of patients with established diagnoses but is rarely used as first step of the diagnostic process substituting a personal contact with a health professional. We report on the diagnostic validity and cost per patient implications based on a feasibility study of a new virtual diagnostic service (VDS) for common neurological sleep disorders that, as a first step, involves the collection and automated analysis of self-reported digital patient data.MethodsThe VDS was established at the Odense University Hospital, Denmark.

View Article and Find Full Text PDF

Introduction: Glaucoma treatment predominantly involves the use of topical anti-glaucoma eye drops, with patient adherence influenced by individual preferences. This study aimed to assess these preferences and highlight the importance of personalized treatment approaches among ophthalmologists.

Methods: This French multicenter, cross-sectional study involved 21 ophthalmologists-members of the Board of Directors of the French Society of Glaucoma-from both public and private practices, who distributed a standardized questionnaire to their patients with glaucoma.

View Article and Find Full Text PDF

Introduction: No head-to-head studies comparing the efficacy of avalglucosidase alfa (AVA) with cipaglucosidase alfa + miglustat (Cipa+mig) have been conducted in patients with late-onset Pompe disease (LOPD). Two indirect treatment comparisons (ITCs) were conducted to estimate the effects of AVA versus Cipa+mig.

Methods: ITCs were conducted using simulated treatment comparisons (STCs), adjusting for differences in prognostic factors and treatment effect modifiers.

View Article and Find Full Text PDF

Introduction: This post hoc analysis of an A Toujeo Observational Study (ATOS) aims to evaluate the real-world effectiveness and safety of insulin glargine 300 U/ml (Gla-300) in high-risk subgroups of insulin-naïve people with type 2 diabetes (PwT2D) from multiple geographical regions (Asia, the Middle East, North Africa, Latin America, and Eastern Europe).

Methods: In these post hoc analyses of ATOS, a real-world, 12-month, prospective study included 4422 insulin-naïve adults (age ≥ 18 years) with type 2 diabetes (T2D) uncontrolled (HbA > 7% and ≤ 11%) on one or more oral antidiabetic drugs (OADs) who initiated Gla-300 treatment as per routine practice. Primary and secondary endpoints were studied according to renal impairment (RI) status (without or with) and age group ( View Article and Find Full Text PDF

Plasmalogens are a subclass of glycerophospholipids characterized by a vinyl-ether bond at the sn-1 position; they play several physiological roles including membrane stabilization, antioxidant activity, and signal transduction. While choline, ethanolamine, serine, and glycerol plasmalogens (PlsCho, PlsEtn, PlsSer, and PlsGro) are naturally abundant, inositol plasmalogens (PlsIns) are rare. In contrast to the limited occurrence of PlsIns, phosphatidylinositol is a biologically crucial lipid, and its enzymatic biosynthesis from phosphatidylcholine has been extensively studied.

View Article and Find Full Text PDF